Compare INVH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INVH | GH |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 17.3B |
| IPO Year | 2016 | 2018 |
| Metric | INVH | GH |
|---|---|---|
| Price | $29.63 | $136.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 19 |
| Target Price | $32.50 | ★ $119.79 |
| AVG Volume (30 Days) | ★ 5.6M | 2.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 29.73 | 6.74 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $2,729,296,000.00 | $982,021,000.00 |
| Revenue This Year | $2.92 | $33.30 |
| Revenue Next Year | $2.43 | $28.27 |
| P/E Ratio | $111.73 | ★ N/A |
| Revenue Growth | 4.21 | ★ 32.88 |
| 52 Week Low | $24.25 | $40.36 |
| 52 Week High | $33.21 | $135.00 |
| Indicator | INVH | GH |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 67.61 |
| Support Level | $27.54 | $97.16 |
| Resistance Level | $30.12 | N/A |
| Average True Range (ATR) | 0.56 | 6.49 |
| MACD | -0.09 | -0.86 |
| Stochastic Oscillator | 74.47 | 74.77 |
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.